VANI Feb 2025 2.000 call
| Previous close | 0.1000 |
| Open | 0.1000 |
| Bid | 0.1000 |
| Ask | 0.3000 |
| Strike | 2.00 |
| Expiry date | 2025-02-21 |
| Day's range | 0.1000 - 0.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 322 |
Business WireVivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
ALAMEDA, Calif., September 26, 2024--Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today announced that the Bellberry Human Research Ethics Committee ("HREC") has approved and the Therapeutic Goods Administration ("TGA") in Australia has formally acknowledged a first in human clinical trial of the Company’s miniature, subdermal GLP-1 (exenatide) implant in obese and overweight subjects.
GlobeNewswirePresenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now
MIAMI, Sept. 24, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 75th Emerging Growth Conference on September 25 & 26, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting c
Business WireVivani Medical to Present at the Emerging Growth Conference on September 25, 2024
ALAMEDA, Calif., September 23, 2024--Vivani Medical, Inc. (NASDAQ: VANI) (the "Company" or "Vivani"), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that it will present at the Emerging Growth Conference on September 25, 2024.
